Catalyst

Slingshot members are tracking this event:

Ionis Pharma (IONS) to finish Phase 2 study of IONIS-FXIrx administered to Patients with End-Stage Renal Disease on Hemodialysis in Fall 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IONS

100%
BAYRY

100%

Additional Information

Additional Relevant Details Update on 9.12.16: Estimated Study Completion Date:November 2016
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 01, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Study, End-stage Renal Disease, Hemodialysis, Ionis-fxi, Ionis-fxirx